Dr. Su’s research focus is experimental therapeutics for cancer metastasis, a deadly stage when the cancer cells move from the primary site to establish tumors at distant sites. Her laboratory uses cell and mouse models of breast and pancreatic cancer, and techniques of cell and molecular biology, biochemistry, and in situ imaging to elucidate drug efficacy, cell signaling, the role of the tumor microenvironment (macrophages, neutrophils, T cells), and therapy resistance mechanisms during cancer metastasis. Her group is specifically involved with the characterization and development of new inhibitors of the small GTP binding proteins Rac and Cdc42 as targeted therapeutics for cancer metastasis.